[This Week's IPO] Demand Forecast and Subscription Schedule for the First Week of August

In the first week of this month (August), companies such as Yuracle, IronDevice, NextBioMedical, Jeonjin Construction Robot, K3i, TDS Pharm, M83, and EnCell will conduct demand forecasting targeting institutional investors. Bankware Global is preparing for a general subscription.

◆Yuracle= Founded in 2001, Yuracle has successfully completed over 1,000 customer projects in the mobile platform software market. It provides optimal software and services for mobile environments, covering app development, operation, and maintenance for mobile businesses, and is especially leading mobile standardization for large corporate groups.

The total number of shares offered is 751,000, with a desired offering price band of KRW 18,000 to 21,000 per share. From July 29 to August 2, a five-business-day demand forecasting will be conducted targeting institutional investors to finalize the offering price, followed by a general subscription on August 6-7, aiming for listing. The lead underwriter is Kiwoom Securities.

◆IronDevice= Established in 2008 by former employees of Samsung Electronics and Fairchild Semiconductor, IronDevice provides single-chip design integrating digital, analog, and power technologies along with advanced software technology. It is notably the only domestic manufacturer of smart audio amplifier chips, standing out in the high-performance audio amplifier chip market.

The total planned offering is 3 million shares, with a desired price range of KRW 4,900 to 5,700 per share, and a total offering amount of KRW 14.7 billion to 17.1 billion. From July 29 to August 2, demand forecasting targeting institutional investors will be conducted to finalize the offering price, followed by a two-day subscription starting August 7. The lead underwriter is Daishin Securities.

◆NextBioMedical= Founded in 2014, NextBioMedical leads the innovative therapeutic agent market by developing the world's first ▲endoscopic hemostatic agent ‘NexpowderTM’ ▲vascular embolic microparticles ‘NexsphereTM’ and musculoskeletal pain embolic therapeutic agent ‘Nexsphere-FTM’.

A total of 1 million shares will be offered. The planned offering price is KRW 24,000 to 29,000 per share, with a total offering amount of KRW 24 billion to 29 billion. Demand forecasting will be conducted from July 29 to August 2, followed by subscription on August 7-8, aiming for listing on the KOSDAQ market within August. The lead underwriter is Korea Investment & Securities.

◆Jeonjin Construction Robot= Jeonjin Construction Robot is a subsidiary of Motrex, a KOSDAQ-listed company, and the largest domestic manufacturer of concrete pump cars (CPC). A concrete pump car (CPC) is essential construction equipment that pumps cement or concrete on construction sites, enabling high-rise and long-distance pouring work.

A total of 3,077,650 shares will be offered. The desired offering price per share is KRW 13,800 to 15,700, with a total planned offering amount of approximately KRW 42.5 billion to 48.3 billion. Demand forecasting targeting institutions will be conducted over five days from July 30 to August 5, followed by a general subscription on August 8-9, aiming for listing within August. The lead underwriter is Mirae Asset Securities.

◆K3i= Founded in 2000, K3i is the only domestic developer of the ‘Universe XR Framework’, an XR middleware solution. The ‘XR middleware solution’ is an open software essential for XR content development and execution, and K3i was the first in Korea to develop this core technology in 2015.

This listing will offer 1.4 million shares. The desired offering price band is KRW 12,500 to 15,500 per share. Demand forecasting will be conducted from July 30 to August 5 to finalize the offering price, followed by subscription on August 8-9, aiming for listing on the KOSDAQ market. The lead underwriter is Hana Securities.

◆TDS Pharm= Established in 2002, TDS Pharm is a company primarily engaged in the development and manufacturing of transdermal drug delivery systems (TDDS), a high-growth segment within drug delivery systems (DDS). TDDS is a drug delivery system that administers drugs through the skin at a controlled rate.

A total of 1 million new shares will be issued. The offering price per share is KRW 9,500 to 10,700, with a total offering amount of KRW 9.5 billion to 10.7 billion. Demand forecasting targeting institutional investors will be conducted from July 31 to August 6 to finalize the offering price, followed by general subscription from August 9 to 12. The lead underwriter is Korea Investment & Securities.

◆M83= M83, established in February 2020, is a VFX (Visual Effects) specialized company. It has served as the main studio for large-scale VFX on films such as ‘Noryang: Sea of Death’, ‘Hansan: Rising Dragon’, ‘Space Sweepers’, and dramas like ‘Vincenzo’ and ‘Sweet Home 2’.

A total of 1.5 million shares will be offered entirely as new shares. The planned offering price is KRW 11,000 to 13,000 per share. Demand forecasting targeting institutional investors will be conducted from August 1 to 7, followed by general subscription on August 12-13. The lead underwriters are ShinYoung Securities and Eugene Investment & Securities.

◆EnCell= EnCell was founded in 2018 by Professor Jang Jong-wook of Samsung Seoul Hospital as a faculty startup. It operates ▲cell and gene therapy CDMO business and ▲next-generation mesenchymal stem cell therapy (EN001) new drug development targeting rare and intractable muscle diseases such as Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy (DMD), and sarcopenia.

The total number of shares offered is 1,566,800, with a desired offering price band of KRW 13,600 to 15,300. Demand forecasting will be conducted from August 2 to 8, followed by general subscription on August 12-13. The lead underwriter is NH Investment & Securities.

◆Bankware Global= The desired offering price band per share is KRW 16,000 to 19,000. Demand forecasting targeting institutional investors will be conducted until July 29 to finalize the offering price, followed by general subscription on August 1-2, aiming for listing. The lead underwriter is Mirae Asset Securities.

Founded in 2010, Bankware Global has built a unique competitive edge by developing core banking packages. It has supplied packages to MyBank, Alibaba's internet bank in China, K Bank in Korea, and Line Bank in Taiwan, and currently has over 100 clients across seven Asian countries, including ▲financial public institutions ▲commercial banks ▲savings banks ▲card companies ▲capital companies ▲fintech companies.